undamentalytics Newsletter
Sign in

Exagen Inc. income statement

In fiscal 2025, Exagen Inc. reported revenue of $66.6m, up 19.7% on the year before, operating income of −$14.1m (a -21.1% margin) and net income of −$20.0m, or −$0.93 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue324042484653566771
Cost of revenue151917212423232829
Gross profit172225282129333942
Research and development2247105566
Selling, general and administrative202937455247414748
Operating income−5−9−15−24−46−23−14−14−13
Interest expense333322245
Income tax00−00−00000
Net income−8−12−17−27−47−24−15−20−19
Diluted EPS−$293.34−$8.46−$1.32−$1.68−$2.77−$1.34−$0.83−$0.93−$0.80
Diluted shares (average)—4m13m16m17m18m18m22m24m
EBITDA−4−9−15−23−44−21−12−12−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PSNL vs XGNBNR vs XGNCDXS vs XGN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Exagen Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Exagen Inc.